__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

 

Many patients will progress along the MS spectrum to SPMS.

This campaign aims to educate UK healthcare professionals (HCPs) on secondary progressive MS (SPMS) and provide tools and resources to help HCPs to:

Focus icon for earlier patient identification

Drive earlier identification of people with SPMS

Magnifying glass icon for monitoring signs of progression

Monitor for signs of progression, such as cognitive changes, as part of your routine practice

Patient support icon for helping improve quality of life and disease burden

Effectively manage your patients with progressive MS to help improve their quality of life and minimise their burden of disease

Together we want to act on this vital opportunity to effectively manage patients and direct them to the right services.


 

 

*This is not representative of a real patient

 

An introduction to SPMS

Disease course icon for SPMS occurrence after RRMS

SPMS is a stage of disease which follows an initial RRMS course1

Disability icon for SPMS definition

SPMS is defined as progressive accumulated disability with or without occasional relapses, minor remissions, and plateaus2

Pie chart icon for prevalence of progression from RRMS to SPMS

Approximately 85–90% of patients have RRMS at the time of diagnosis3 and 1 in 2 people with RRMS will advance to SPMS within 20 years4

 

The heterogeneity of MS4,5

 

Graph showing the heterogenity of MS over time, highlighting the clinical threshold for disease progression

Adapted from Drendou CA, et al. Nat Rev Immunol. 2015;15(9):545-548 and Larochelle C, et al. Trends Neurosci. 2016;39(5):325-339.

 

Globally, SPMS is the second most common form of MS with a prevalence that varies geographically – up to 57.8/100,000 in the UK3

Despite the recent advances in the understanding of the disease, the diagnosis and treatment of SPMS continues to be challenging in routine clinical practice3,6

 

HCP, healthcare professional; IL, interleukin; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SDMT, symbol digit modalities test; SPMS, secondary progressive multiple sclerosis; TNF, tumour necrosis factor; UK, United Kingdom.

References

  1. National MS Society. Types of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progr.... Accessed November 2021.
  2. Lublin FD, Reingold SC. Neurology. 1996;46(4):907–911.
  3. Inojasa H, et al. J Neurol. 2019;268(4):1210–1221.
  4. Khurana V, Medin J; Poster presented at: the 7th Joint ECTRIM-ACTRIMS Meeting, 25–28 October 2017, Paris, France.
  5. Drendou CA, et al. Nat Rev Immunol. 2015;15(9):545–548.
  6. Larochelle C, et al. Trends Neurosci. 2016;39(5):325‒339.
  7. Bokyo A, et al. Mult Scler Relat Disord. 2021;50:102778. Epub. doi 10.1016/j.msard.2021.102778.
Rate this content: 
Average: 3.2 (86 votes)
UK | December 2021 | 145868
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]